Bristol-Myers Squibb Presents Promising Phase IIb Data for Novel,...

It is the first investigational antiretroviral to prevent initial viral attachment to the host CD4+ T cell and entry into the host immune cell by binding directly to the HIV virus 24 week Phase IIb data showed similar response rates have also been reported to occur in the setting of immune reconstitution; however, the time to onset is more ... (more)

http://ift.tt/1hLVSgf